RxDoctor Payments Data

Konstantinos Arnaoutakis, MD

Hematology & Oncology · Little Rock, ARNPI 1053426304

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $10,360 of the $12,209 with a category attached, or 84.9%. 11 manufacturers reported payments, led by Takeda Pharmaceuticals U.S.A., Inc. at 25.8% of the total. Reporting peaked in 2021 at $4,562 and has fallen 98.4% since, to $74 in 2025.

$12,209in general payments, 2019–2025

Across 18 payments — averaging $678.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$3K
  • E.r. Squibb & Sons, L.L.C.$2K
  • Beigene, Ltd.$2K
  • Jazz Pharmaceuticals Inc.$2K
  • Janssen Scientific Affairs, LLC$1K
  • W. L. Gore & Associates, Inc.$792
  • plus $2K from 5 others
$78,814in research payments, 2019–2025

Across 24 payments — averaging $3283.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • E.r. Squibb & Sons, L.L.C.$25K
  • Cook Research Incorporated$17K
  • Amgen$16K
  • Astrazeneca UK Limited$15K
  • Novartis$4K
  • Genentech, Inc.$2K

What the payments were for

  • Consulting fees$10,36085%
  • Travel & lodging$1,1489%
  • Food & beverage$6896%
  • Education$120%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,209 in reported general payments places this provider in the 70th percentile of 92 hematology & oncology providers in Arkansas.

See all hematology & oncology providers in Arkansas

Medicare billing

Part B allowed, 2024
$56,425
Medicare patients
171
Services billed
603

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CabometyxCabozantinib S-Malate16$397,463
TagrissoOsimertinib Mesylate24$386,607
LorbrenaLorlatinib12$240,702
EliquisApixaban29$18,723
SymbicortBudesonide/Formoterol Fumarate14$4,581
Erlotinib Hcl11$984
Megestrol Acetate15$861
Albuterol Sulfate HfaAlbuterol Sulfate26$780
Prochlorperazine Maleate40$723
Dexamethasone38$695
Potassium Chloride33$579
Ondansetron OdtOndansetron19$430
Mirtazapine17$171
Pantoprazole Sodium24$151
Ondansetron Hcl16$150

Paid to pharmacies, not to this prescriber.

Other hematology & oncology in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →